FRANKLIN LAKES, N.J., Dec. 8, 2014 /PRNewswire/ -- BD Medical, a segment of BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, is presenting its comprehensive solutions for the hospital pharmacy during the 49th American Society of Health-System Pharmacists (ASHP) Midyear Clinical Meeting taking place December 7-11, 2014 at the Anaheim Convention Center in Orange County, California. Building on BD's legacy and commitment to supporting safety and efficiency in healthcare, the solutions on display at Booth #1101 demonstrate a cohesive approach to reducing the possibility of human error, protecting healthcare workers from occupational hazards, standardizing practice, streamlining workflow and increasing efficiency from medication preparation to delivery.
"Despite best efforts, patient and healthcare worker safety can still be compromised during the medication distribution process," said William A. Tozzi, President, BD Medical – Medical Surgical Systems. "Furthermore, as healthcare continues to evolve, there is an increasing demand for better outcomes, while still controlling costs by implementing smarter workflow efficiencies. BD's portfolio of complete hospital pharmacy solutions is specifically designed to address these challenges by enhancing patient and healthcare worker safety, improving workflow efficiencies and helping to facilitate compliance to evolving guidelines and standards."
The exhibit will provide an experiential view of BD's solutions developed to help combat against the difficult task pharmacy practice leaders face in balancing quality improvements, compounding legislations changes and drug shortages while continuing to meet cost reduction expectations.
BD's experiential Booth #1101 will showcase:
BD Cato™ Medication Workflow Solutions: an automated pharmacy workflow system that detects wrong dose/drug errors in real time, standardizes workflow for medication preparations, automates documentation and optimizes drug utilization to reduce drug waste. The system provides a robust interface with Pharmacy IT systems to automatically pull in medication orders and allow dose queue management within the preparation environment, and provides a range of reports and analytics to help improve safety and efficiency. This year, BD will be showcasing a new camera-based visual documentation system ahead of launch in February 2015, which will enable remote dose verification and image documentation.
BD Diabetes Care and AutoShield Duo™: the BD AutoShield Duo pen needle is the only safety pen needle in the U.S. that provides both front and back end passive needle protection to lower the risk of accidental needlestick injuries, and supports the current AADE practice advisory for injection technique guidelines calling for the use of shorter needles, proper site rotation and using needles only one time. For 90 years, BD's culture of innovation and continuous improvement has enhanced the patient experience to help improve therapy and outcomes for people with diabetes worldwide.
BD Disposal Solutions: are collectors specifically designed to safely contain sharps, non-hazardous pharmaceutical, chemotherapy and hazardous RCRA waste. The collectors come in a variety of colors and sizes to meet disposal needs and are safe for incineration.
BD Enteral Syringe with BD UniVia™ Connector: is designed to reduce the risk of tubing set misconnections, which may lead to medication errors. This helps to safely deliver nourishment and oral medications.
BD Medication Preparation Products: including BD™ Filter and BD Nokor™ needles, BD Sterile Syringe Convenience Trays, BD Tip Cap Trays, BD Oral Syringe System and BD PosiFlush™ Pre-Filled Syringes are designed to enhance the medication preparation and delivery process.
BD PhaSeal™ System: a closed-system drug transfer device (CSTD) that reduces healthcare workers' exposure to hazardous, parenteral medications from preparation in the pharmacy to administration with the patient. The BD PhaSeal System is an airtight and leak-proof CSTD that mechanically prohibits the transfer of environmental contaminants into the system and the escape of drug or vapor concentrations outside the system, thereby minimizing individual and environmental exposure to drug vapor aerosols and spills. The system also prevents microbial ingress. With a limited number of components and only one connection interface, the BD PhaSeal System dimensions are created to ISO standards to be compatible with all standard size drug vials and tubing.
BD Simplist™ Prefilled Injectables: are ready-to-administer, prefilled injectables designed to reduce the potential risk of medication error. Individually packaged, clearly labeled and bar-coded ready-to-administer (RTA) injectables enable compliance with The Joint Commission Medication Management standards.
Intelliport® System: a medication management solution for manual IV bolus injections that automatically identifies the IV injectable drug name and concentration, performs real-time allergy checks before an injection, measures the cumulative dose being administered to a patient during an injection and wirelessly sends captured information on drug/dose/time directly into the patient's electronic medical record following an injection. The Intelliport® System is currently under FDA review. Intelliport is a trademark of CRISI Medical Systems, Inc.
For more information, please visit www.bd.com.
About BD BD is a leading medical technology company that partners with customers and stakeholders to address many of the world's most pressing and evolving health needs. Our innovative solutions are focused on improving drug delivery, enhancing the diagnosis of infectious diseases and cancers, supporting the management of diabetes and advancing cellular research. We are more than 30,000 associates in 50 countries who strive to fulfill our purpose of "Helping all people live healthy lives" by advancing the quality, accessibility, safety and affordability of healthcare around the world. For more information, please visit www.bd.com.
Contact: Matt Coppola Public Relations (201) 847-7370 Matthew_R_Coppola@bd.com
SOURCE BD (Becton, Dickinson and Company)